Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
TECK$59.05+0.15(+0.25%)Teck Provides Update on Highland Valley Copper Operations[3:18:56 PM ET]AXON$422.00+7.40(+1.78%)Axon Announces Body 5: Next-Generation Camera Built for the AI Era Axon (Nasdaq: AXON), the global leader in public safety technology, today announced Axon Body 5, its newest body-worn camera designed to bring more...[1:00:00 PM ET]PFE$30.02-0.40(-1.31%)Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026[11:18:00 AM ET]BIVI$1.24-0.04(-3.13%)From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television[10:30:00 AM ET]AMGN$439.26-8.02(-1.79%)IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's...[10:30:00 AM ET]JNJ$263.81-3.80(-1.42%)Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of...[8:54:00 AM ET]PBLS$24.79-2.13(-7.91%)Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors[8:45:00 AM ET]SMTC$131.80+6.68(+5.34%)Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026[8:00:00 AM ET]GMAB$43.85+3.85(+9.63%)Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]INCY$115.00-1.93(-1.65%)Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]NBTX$29.36+0.17(+0.58%)NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma[7:00:00 AM ET]
News desk

Live news

Stock news, press releases, and legal notices, with ticker, type, source, and time. Signed-out visitors and Free accounts see the last year, 15 minutes behind. Pro, including the 7-day trial, sees the full archive as each headline is ingested.

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
TYGO Legal ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tigo Energy, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TYGO Newsfile Corp
Press release Uniting for Shared Growth, Linking the World: 2026 FHC Future Health Industry Conference Successfully Held in Hangzhou Newsfile Corp
BABA Stock news Alibaba vs. Booking: Which Travel Provider Stock Is a Better Buy in 2026? The Motley Fool
OKLO Stock news Oklo Is Down 61% This Year Despite a Real Technical Milestone. Here's the Disconnect Between the Stock and the Science. The Motley Fool
ADBE Stock news Adobe: A Fairly Priced Compounder In An Expensive Market Seeking Alpha
TECK Press release Teck Provides Update on Highland Valley Copper Operations GlobeNewswire
BX Stock news Blackstone: 3 Key Takeaways for Long-Term Investors The Motley Fool
VERX Stock news Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. The Motley Fool
XTIA Legal XTIA FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages XTI Aerospace, Inc. Investors to Secure Counsel Before Important October 27 Deadline in Securities Class Action - XTIA Newsfile Corp
AAPL Stock news Peter Thiel says Apple has done 'nothing new' after Steve Jobs Business Insider
IBB Stock news Biotech stocks are surging. How investors can play the new drug innovation boom CNBC
HBM Stock news SK hynix: Don't Bet On The Slower Boat In A Fast Tide Seeking Alpha
CTY Stock news Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere Barrons
E Stock news Eni: I Sold Out In Early/Mid-2026 And Why I Won't Buy Back Here (Downgrade) Seeking Alpha
UNP Stock news Union Pacific Corporation: 3 Key Takeaways for Long-Term Investors The Motley Fool
SPCX Stock news SpaceX's "Super Intelligence" Segment Just Made the Stock a Must-Own The Motley Fool
SBS Legal CCC Investors Have Opportunity to Join CCC Intelligent Solutions Holdings Inc. Fraud Investigation with SBS Law Business Wire
MSFT Stock news Microsoft Q1: A $744 Billion AI Reckoning Is Coming Seeking Alpha
BKNG Stock news Advance Auto Parts vs. Booking Holdings: Which Consumer Stock Is a Better Buy in 2026? The Motley Fool
MGHL Stock news Energy Transfer vs. Kinder Morgan: Which Natural Gas Pipeline Stock Is the Better Buy for the AI Power Boom? The Motley Fool
Market Pulse

The same desk, in your inbox.

Market Pulse picks three headlines from the day, names the stock that moved, and shows the call that returns each one.

Monday, Wednesday, and Friday. Unsubscribe from any issue, or from account settings if you have one.

FAQ

Frequently asked questions

Is the live news desk the same feed as the API?
The desk shows the same articles in the browser: ticker, type, source, and published time. Signed-out visitors and Free accounts see the last year, 15 minutes behind. Pro, including the 7-day trial, sees the full archive as soon as a row is ingested. A Free API key returns the last year. Pro keys search the full archive and also include the summary and the original URL.
Why is the live news desk delayed?
Signed-out visitors and Free accounts see this desk 15 minutes behind ingestion, across the last year of headlines. Pro, including the 7-day trial, sees the full archive as soon as headlines are ingested. A Free API key has the same 15-minute delay. The delay is the plan, not an outage, and the status page stays green while the delayed view is on.
How far back does the live news desk go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices, 15 minutes behind ingestion. Pro, including the 7-day trial, sees the full archive as new rows are ingested. Page size is 20. A Free API key returns the last year. Pro keys search the full archive.
How do I see stock news without the 15-minute delay?
Start the 7-day Pro trial and sign in. A card is required. Pro is $15 a month, or $162 a year, and this desk then shows the full archive as headlines are ingested. Signed-out visitors and Free accounts still see the last year of headlines 15 minutes behind. A Free API key stays at 100 requests a day, the same delay, and the last year. One trial per email.
What do the columns on the news desk mean?
Ticker is the symbol attached to the article. Type is stock news, press release, or legal. Headline is the title. Source is the publisher or wire. Published is the article time in Eastern Time. Page size is 20. Use the type buttons when you want wires only, or legal notices kept out of the list.
Can I search the live news desk by ticker?
Yes. The desk has a ticker search, a headline search, a source menu, and buttons for stock news, press releases, and legal notices. Those filters stay on this page. The same filters exist on GET /v1/news if you want the JSON, including the summary and the original URL. Page size on the desk is 20.
How often do new stock headlines appear?
Sources are polled every second, including nights and weekends. Pro, including the 7-day trial, sees a row as soon as it is ingested. Signed-out visitors and Free accounts see that same row 15 minutes later. The desk is a browser view of the API feed, not a second dataset.